Bridge the Gap - SYNGAP Education and Research Foundation is excited to announce we will be hosting the first
SYNGAP1: Patient-Focused Drug Development Meeting in the United States.
Bridge the Gap is one of only 30 organizations selected by the FDA to hold an Externally Led - PFDD meeting, since the FDA program began in 2012.
Learn more about why this PFDD Meeting is a critical step in our strategy to help help accelerate the research pathway toward new therapeutic treatments for those affected by SYNGAP1. Learn more about Patient Focused Drug Development Meetings on the FDA PFDD Website
Check out what other patient advocacy organizations are sharing about their experiences and how they benefited from hosting a PFDD Meeting - Here: Taking Stock of PFDD: A Vibrant Future for Patient-Focused Drug Development.
BTG's PFDD Meeting will be held as a virtual, live-stream event, that is accessible and free to all SYNGAP1 Community Stakeholders. The meeting will have guest moderators and include a participating panel of SYNGAP1 patients/families/caregivers,families; SYNGAP1 clinical/research experts and regulatory experts. Virtual attendees will have opportunities to ask questions and provide comments during the meeting and for 30 days post-meeting.
Please contact us with any questions you may have regarding this meeting.